Entera Bio prices $275M private placement led by BVF Partners

Entera Bio Ltd. (NASDAQ: ENTX) has priced an oversubscribed private placement expected to generate approximately $275 million in gross proceeds, before placement agent fees and other expenses, according to a statement from the Tel Aviv-based company.

The offering is led by existing investor BVF Partners L.P., with participation from new investors including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management.

Under the terms of the securities purchase agreement, Entera agreed to issue 122,961,215 ordinary shares at $2.04 per share, along with pre-funded warrants to purchase up to 11,842,695 additional ordinary shares at $2.04 minus a nominal exercise price. The offering was priced at the market under Nasdaq rules and is expected to close on or about July 28, 2026.

Upon closing, Entera has agreed to grant BVF the right to designate two directors to its board, subject to applicable legal and Nasdaq requirements.

The company stated that net proceeds, combined with existing cash, are expected to fund operations into 2030. Planned uses include fully funding a Phase 3 registrational program for EB613, an oral PTH(1-34) tablet candidate for osteoporosis, advancing EB612 into Phase 1 development for hypoparathyroidism in collaboration with OPKO Health, and general corporate purposes.

Leerink Partners is acting as lead placement agent. Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital, and Canaccord Genuity are serving as co-placement agents.

The securities have not been registered under the Securities Act of 1933 and may not be resold in the United States absent an effective registration statement or applicable exemption.

You May Also Be Interested In

• Entera Bio prices $275 million private placement led by BVF Partners
• Youlife receives Nasdaq notice for falling below $1 minimum bid
• Processa acquires Vidya Therapeutics in $200M private placement deal